HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Traditional Chinese Medicine (570.HK) - Will This Privatization Rumor Come True ?

China Healthcare Weekly (Feb.12) - New Pricing Mechanism for Drugs, China Biotech M&A, Medicilon

I-Mab to Divest Chinese Assets and Business Operations for up to $80M - An Escape by Crafty Scheme

Wuxi Biologics (2269.HK) - The Latest Updates Related to 2024 Performance Worth the Attention

WuXi AppTec (2359.HK/603259.CH) - Behind the Plunge Is a War

WuXi XDC Cayman (2268.HK) - Would It Be An "Oasis in the Desert"?

Wuxi Biologics (2269.HK) - Dramatic Changes in Management Forecasts Fail to Bring Back Confidence

Equity Bottom-Up

<ul>
<li>Based on the latest updates, it's still uncertain to see a positive turnaround.There've been no effective ways to evade.Debate about restricting Chinese biopharmaceuticals has never gone away in US politics.</li>
<li>Nobody can say with 100% certainty whether the Bill will be passed/how much impact it will have. Until the dust settles, any rebound in share prices is difficult to sustain.</li>
<li>The market is preparing for the worst-case scenario, but if the final Bill is less stringent than expected, shares of WuXi AppTec and its subsidiaries would rebound.Here're different bottom-fishing strategies.</li>
</ul>


Based on the latest updates, it's still uncertain to see a positive turnaround.There've been no effective ways to evade.Debate about restricting Chinese biopharmaceuticals has never gone away in US politics.
Nobody can say with 100% certainty whether the Bill will be passed/how much impact it will have. Until the dust settles, any rebound in share prices is difficult to sustain.
The market is preparing for the worst-case scenario, but if the final Bill is less stringent than expected, shares of WuXi AppTec and its subsidiaries would rebound.Here're different bottom-fishing strategies.


Latest Impact of the US Biosecure Act on WuXi AppTec/WuXi Bio/WuXi XDC - China CXO Really Game Over?